BioStem Technologies, Inc. (OTCMKTS:BSEM) Short Interest Up 41.1% in September

BioStem Technologies, Inc. (OTCMKTS:BSEM) was the target of a significant growth in short interest in September. As of September 30th, there was short interest totalling 88,600 shares, a growth of 41.1% from the September 15th total of 62,800 shares. Based on an average daily trading volume, of 57,200 shares, the days-to-cover ratio is presently 1.5 days.

BioStem Technologies Stock Down 2.3 %

BioStem Technologies stock traded down 0.26 during mid-day trading on Friday, reaching 10.89. 21,900 shares of the company’s stock were exchanged, compared to its average volume of 27,344. The firm has a market capitalization of $177.29 million, a PE ratio of 27.91 and a beta of 0.05. BioStem Technologies has a one year low of 2.26 and a one year high of 15.50. The business’s fifty day simple moving average is 10.56 and its 200 day simple moving average is 9.79.

BioStem Technologies (OTCMKTS:BSEM) last announced its earnings results on Monday, August 12th. The company reported 0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of 0.12 by 0.18. The business had revenue of 74.49 million for the quarter, compared to analysts’ expectations of 43.99 million. On average, sell-side analysts forecast that BioStem Technologies will post 1.13 earnings per share for the current year.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.